Blood test identified a DNA methylation marker linked to lifetime cannabis use

An epigenome-wide study of over 2,500 women identified and replicated a blood-based DNA methylation site associated with lifetime cannabis use, though its predictive accuracy was modest.

Markunas, Christina A et al.·American journal of medical genetics. Part B·2021·Moderate EvidenceObservational
RTHC-03323ObservationalModerate Evidence2021RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Observational
Evidence
Moderate Evidence
Sample
N=1,730

What This Study Found

Researchers identified a replicated association between lifetime cannabis use and DNA methylation at site cg15973234 in the CEMIP gene (combined P = 3.3 x 10^-8). The methylation-based classifier had modest predictive accuracy with AUC of 0.60 in discovery and 0.54 in replication samples.

Key Numbers

Discovery N = 1,730 (855 ever-users); replication N = 853 (392 ever-users); cg15973234 in CEMIP gene P = 3.3 x 10^-8; AUC 0.60 discovery, 0.54 replication

How They Did This

Epigenome-wide association study using blood-based DNA methylation data from a case-cohort within the Sister Study (discovery N = 1,730; replication N = 853). Researchers tested associations between methylation at over 450,000 sites and self-reported lifetime cannabis use.

Why This Research Matters

Objective biomarkers of cannabis use are needed for epidemiological research. While urine and blood tests detect recent use, DNA methylation could potentially serve as a marker of cumulative lifetime exposure, capturing long-term use patterns that self-report may miss.

The Bigger Picture

This is the first blood-based epigenome-wide study of cannabis use. While the predictive accuracy is too modest for clinical use, the replicated finding at CEMIP suggests cannabis leaves a detectable molecular footprint that could improve epidemiological research.

What This Study Doesn't Tell Us

All-female cohort (Sister Study) limits generalizability. Modest predictive accuracy. Cannot distinguish frequency, recency, or duration of use. Self-reported cannabis use as the comparator.

Questions This Raises

  • ?Does this methylation change have functional consequences?
  • ?Would it perform better in populations with heavier use patterns?
  • ?Could combining multiple methylation sites improve prediction?
  • ?Does the CEMIP methylation change persist after cessation?

Trust & Context

Key Stat:
First replicated blood-based epigenetic marker of lifetime cannabis use
Evidence Grade:
Well-powered EWAS with independent replication, though the effect size is small and the cohort is all-female.
Study Age:
Published in 2021.
Original Title:
Epigenome-wide analysis uncovers a blood-based DNA methylation biomarker of lifetime cannabis use.
Published In:
American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, 186(3), 173-182 (2021)
Database ID:
RTHC-03323

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Watches what happens naturally without intervening.

What do these levels mean? →

Frequently Asked Questions

Can a blood test tell if someone has ever used cannabis?

This study found a DNA methylation signal associated with lifetime cannabis use, but its accuracy was too modest (AUC 0.54-0.60) for reliable individual-level detection.

What is DNA methylation?

DNA methylation is a chemical modification to DNA that can change how genes are expressed without altering the genetic code itself. Environmental exposures, including substance use, can alter methylation patterns.

Read More on RethinkTHC

Cite This Study

RTHC-03323·https://rethinkthc.com/research/RTHC-03323

APA

Markunas, Christina A; Hancock, Dana B; Xu, Zongli; Quach, Bryan C; Fang, Fang; Sandler, Dale P; Johnson, Eric O; Taylor, Jack A. (2021). Epigenome-wide analysis uncovers a blood-based DNA methylation biomarker of lifetime cannabis use.. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, 186(3), 173-182. https://doi.org/10.1002/ajmg.b.32813

MLA

Markunas, Christina A, et al. "Epigenome-wide analysis uncovers a blood-based DNA methylation biomarker of lifetime cannabis use.." American journal of medical genetics. Part B, 2021. https://doi.org/10.1002/ajmg.b.32813

RethinkTHC

RethinkTHC Research Database. "Epigenome-wide analysis uncovers a blood-based DNA methylati..." RTHC-03323. Retrieved from https://rethinkthc.com/research/markunas-2021-epigenomewide-analysis-uncovers-a

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.